Lack of protective effect of local administration of triamcinolone or systemic treatment with methylprednisolone against damages caused by optic nerve crush in rats

Experimental Eye Research

Volumn 92, Issue 2, 2011, Pages 112-119

  Huang, Tzu Lun ^a   Chang, Chung Hsing ^c   Lin, Kung Hung ^a   Sheu, Min Muh ^a,b   Tsai, Rong Kung ^a,b  

^a BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^b TZU CHI UNIVERSITY   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Flash visual evoked potentials; Methylprednisolone; Neuroprotection; Optic nerve crush; Rat model; RGC density; Triamcinolone

Indexed keywords

FLUOROGOLD; METHYLPREDNISOLONE SODIUM SUCCINATE; MITOGEN ACTIVATED PROTEIN KINASE; PLACEBO; PROTEIN SERINE THREONINE KINASE; STAT3 PROTEIN; TRIAMCINOLONE ACETONIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL DEATH; CELL DENSITY; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFECT; EVOKED VISUAL RESPONSE; HISTOLOGY; IMMUNOHISTOCHEMISTRY; LOADING DRUG DOSE; MACROPHAGE; MALE; MICROGLIA; NERVE CRUSH; NEUROPROTECTION; NICK END LABELING; NONHUMAN; OPTIC NERVE INJURY; PRIORITY JOURNAL; RAT; RETINA; RETINA GANGLION CELL; UPREGULATION; VISION; WESTERN BLOTTING;

ADMINISTRATION, TOPICAL; ANIMALS; BLOTTING, WESTERN; CELL COUNT; ECTODYSPLASINS; EVOKED POTENTIALS, VISUAL; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GLUCOCORTICOIDS; IN SITU NICK-END LABELING; INJECTIONS, INTRAPERITONEAL; METHYLPREDNISOLONE HEMISUCCINATE; NERVE CRUSH; NERVE DEGENERATION; NEUROPROTECTIVE AGENTS; OPTIC NERVE; OPTIC NERVE INJURIES; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RETINAL GANGLION CELLS; STAT3 TRANSCRIPTION FACTOR; TRIAMCINOLONE ACETONIDE;

EID: 79451468770     PISSN: 00144835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exer.2010.12.008     Document Type: Article

References (36)

1. Bracken, M.B., 2002. Steroids for acute spinal cord injury. Cochrane Database Syst. Rev. CD001046.
2. Bracken M.B., Shepard M.J., Collins W.F., Holford T.R., Young W., Baskin D.S., Eisenberg H.M., Flamm E., Leo-Summers L., Maroon J. A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study. N. Engl. J. Med. 1990, 322:1405-1411.
3. Bracken M.B., Shepard M.J., Holford T.R., Leo-Summers L., Aldrich E.F., Fazl M., Fehlings M., Herr D.L., Hitchon P.W., Marshall L.F., Nockels R.P., Pascale V., Perot P.L., Piepmeier J., Sonntag V.K., Wagner F., Wilberger J.E., Winn H.R., Young W. Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the Third National Acute Spinal Cord Injury Randomized controlled Trial. National Acute Spinal Cord Injury Study. J. Am. Med. Assoc. 1997, 277:1597-1604.
4. Cook M.W., Levin L.A., Joseph M.P., Pinczower E.F. Traumatic optic neuropathy. A meta-analysis. Arch. Otolaryngol. Head Neck Surg. 1996, 122:389-392.
5. Diem R., Hobom M., Maier K., Weissert R., Storch M.K., Meyer R., Bahr M. Methylprednisolone increases neuronal apoptosis during autoimmune CNS inflammation by inhibition of an endogenous neuroprotective pathway. J. Neurosci. 2003, 23:6993-7000.
6. Dimitriu C., Bach M., Lagreze W.A., Jehle T. Methylprednisolone fails to preserve retinal ganglion cells and visual function after ocular ischemia in rats. Invest. Ophthalmol. Vis. Sci. 2008, 49:5003-5007.
7. Entezari M., Rajavi Z., Sedighi N., Daftarian N., Sanagoo M. High-dose intravenous methylprednisolone in recent traumatic optic neuropathy; a randomized double-masked placebo-controlled clinical trial. Graefes Arch. Clin. Exp. Ophthalmol. 2007, 245:1267-1271.
8. Grover, D., Li, T.J., Chong, C.C., 2008. Intravitreal steroids for macular edema in diabetes. Cochrane Database Syst. Rev. CD005656.
9. Hall E.D. The neuroprotective pharmacology of methylprednisolone. J. Neurosurg. 1992, 76:13-22.
10. Jehle T., Wingert K., Dimitriu C., Meschede W., Lasseck J., Bach M., Lagreze W.A. Quantification of ischemic damage in the rat retina: a comparative study using evoked potentials, electroretinography, and histology. Invest. Ophthalmol. Vis. Sci. 2008, 49:1056-1064.
11. Johnson K.S., Chu D.S. Evaluation of sub-tenon triamcinolone acetonide injections in the treatment of scleritis. Am. J. Ophthalmol. 2010, 149:77-81.
12. Jonas J.B., Spandau U.H., Harder B., Sauder G. Intravitreal triamcinolone acetonide for treatment of acute nonarteritic anterior ischemic optic neuropathy. Graefes Arch. Clin. Exp. Ophthalmol. 2007, 245:749-750.
13. Kermer P., Klocker N., Labes M., Bahr M. Insulin-like growth factor-I protects axotomized rat retinal ganglion cells from secondary death via PI3-K-dependent Akt phosphorylation and inhibition of caspase-3 in vivo. J. Neurosci. 2000, 20:2-8.
14. Levin L.A., Baker R.S. Management of traumatic optic neuropathy. J. Neuroophthalmol. 2003, 23:72-75.
15. Levin L.A., Beck R.W., Joseph M.P., Seiff S., Kraker R. The treatment of traumatic optic neuropathy: The International Optic Nerve Trauma Study. Ophthalmology 1999, 106:1268-1277.
16. Levkovitch-Verbin H., Quigley H.A., Martin K.R., Zack D.J., Pease M.E., Valenta D.F. A model to study differences between primary and secondary degeneration of retinal ganglion cells in rats by partial optic nerve transection. Invest. Ophthalmol. Vis. Sci. 2003, 44:3388-3393.
17. Luo J.M., Cen L.P., Zhang X.M., Chiang S.W., Huang Y., Lin D., Fan Y.M., van Rooijen N., Lam D.S., Pang C.P., Cui Q. PI3K/akt, JAK/STAT and MEK/ERK pathway inhibition protects retinal ganglion cells via different mechanisms after optic nerve injury. Eur. J. Neurosci. 2007, 26:828-842.
18. Macharadze T., Goldschmidt J., Marunde M., Wanger T., Scheich H., Zuschratter W., Gundelfinger E.D., Kreutz M.R. Interretinal transduction of injury signals after unilateral optic nerve crush. Neuroreport 2009, 20:301-305.
19. Mizuno S., Nishiwaki A., Morita H., Miyake T., Ogura Y. Effects of periocular administration of triamcinolone acetonide on leukocyte-endothelium interactions in the ischemic retina. Invest. Ophthalmol. Vis. Sci. 2007, 48:2831-2836.
20. Nakazawa T., Shimura M., Tomita H., Akiyama H., Yoshioka Y., Kudou H., Tamai M. Intrinsic activation of PI3K/Akt signaling pathway and its neuroprotective effect against retinal injury. Curr. Eye Res. 2003, 26:55-63.
21. Nan K., Sun S., Li Y., Qu J., Li G., Luo L., Chen H., Cheng L. Characterisation of systemic and ocular drug level of triamcinolone acetonide following a single sub-tenon injection. Br. J. Ophthalmol. 2010, 94:654-658.
22. Ohlsson M., Mattsson P., Svensson M. A temporal study of axonal degeneration and glial scar formation following a standardized crush injury of the optic nerve in the adult rat. Restor. Neurol. Neurosci. 2004, 22:1-10.
23. Ohlsson M., Westerlund U., Langmoen I.A., Svensson M. Methylprednisolone treatment does not influence axonal regeneration or degeneration following optic nerve injury in the adult rat. J. Neuroophthalmol. 2004, 24:11-18.
24. Rabchevsky A.G., Fugaccia I., Sullivan P.G., Blades D.A., Scheff S.W. Efficacy of methylprednisolone therapy for the injured rat spinal cord. J. Neurosci. Res. 2002, 68:7-18.
25. Rosner M., Solberg Y., Turetz J., Belkin M. Neuroprotective therapy for argon-laser induced retinal injury. Exp. Eye Res. 1997, 65:485-495.
26. Schroeter M., Jander S. T-cell cytokines in injury-induced neural damage and repair. Neuromolecular Med. 2005, 7:183-195.
27. Sheng Y., Zhu Y., Wu L. Effect of high dosage of methylprednisolone on rat retinal ganglion cell apoptosis after optic nerve crush. Yan Ke Xue Bao 2004, 20:181-186.
28. Shields C.L., Demirci H., Marr B.P., Mashayekhi A., Dai V.V., Materin M.A., Shields J.A. Intravitreal triamcinolone acetonide for acute radiation papillopathy. Retina 2006, 26:537-544.
29. Spencer M.T., Bazarian J.J. Evidence-based emergency medicine/systematic review abstract. Are corticosteroids effective in traumatic spinal cord injury?. Ann. Emerg. Med. 2003, 41:410-413.
30. Steinsapir K.D. Treatment of traumatic optic neuropathy with high-dose corticosteroid. J. Neuroophthalmol. 2006, 26:65-67.
31. Steinsapir K.D., Goldberg R.A., Sinha S., Hovda D.A. Methylprednisolone exacerbates axonal loss following optic nerve trauma in rats. Restor. Neurol. Neurosci. 2000, 17:157-163.
32. Stoll G., Trapp B.D., Griffin J.W. Macrophage function during Wallerian degeneration of rat optic nerve: clearance of degenerating myelin and Ia expression. J. Neurosci. 1989, 9:2327-2335.
33. Tsai R.K., Chang C.H., Sheu M.M., Huang Z.L. Anti-apoptotic effects of human granulocyte colony-stimulating factor (G-CSF) on retinal ganglion cells after optic nerve crush are PI3K/AKT-dependent. Exp. Eye Res. 2010, 90:537-545.
34. Tsai R.K., Chang C.H., Wang H.Z. Neuroprotective effects of recombinant human granulocyte colony-stimulating factor (G-CSF) in neurodegeneration after optic nerve crush in rats. Exp. Eye Res. 2008, 87:242-250.
35. Vaquero J., Zurita M., Oya S., Aguayo C., Bonilla C. Early administration of methylprednisolone decreases apoptotic cell death after spinal cord injury. Histol. Histopathol. 2006, 21:1091-1102.
36. Yu-Wai-Man, P., Griffiths, P.G., 2007. Steroids for traumatic optic neuropathy. Cochrane Database Syst. Rev. CD006032.